Drug-drug Interactions
DDIs were analyzed using Micromedex® (Watson health, IBM Corporation),
and categorized on the basis of severity (contraindicated, major,
moderate, minor) and documentation (excellent, good, fair). DDIs were
included in the analyses if they fit into either of two categories:
Category 1: severity of contraindicated, or severity of major with
excellent/good documentation; or Category 2: severity of moderate with
excellent/good documentation. DDI that did not satisfy criteria for
inclusion in category 1 or 2 were not included in these analyses. DDIs
were also screened for clinical relevance by Lexicomp® (Wolters Kluwer
Health, Hudson, OH), based on having a severity category D or X, which
was selected due to its superior performance for detecting clinically
relevant DDIs.17 Commonly identified DDIs were further
included for analysis. Finally, DDI that generated an alert in MiChart
were classified as having been detected by the EMR (Figure 1).